Cefpodoxime/ETX-1317(Entasis Therapeutics)

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameCefpodoxime/ETX-1317(Entasis Therapeutics)
Drug Alias NameCPD/ETX-1317ETX-1317/CPD
ClassificationOther
Mechanisms of ActionBeta Lactamase inhibitorsCell wall inhibitors
TargetsBeta Lactamase
Therapy Area/IndicationsGram-Negative Bacterial Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEntasis Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesEntasis Therapeutics
Inactive CompaniesN/A
Active IndicationsGram-Negative Bacterial Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A